□ Credit Card
□ Bank Transfer
□ Cheque
(4% surcharge for credit card payments)
Card No:
Expiry Date:
Security Code:
Cardholder's Name:
Cardholder's Signature:
Cardholder's Address:
Cancellations: Received in writing (letter or fax) up to 90 days prior to the event will be subject to a
10% administration fee. Refunds are not possible for cancellations received after this date.
Non-payment: If payment is not made at the time of booking, then invoice will be issued. We reserve
the right to charge credit card details provided at time
Complying with Wearable Health Device RegulationTGA Australia
Complying with Wearable Health Device Regulation
• Which devices does the TGA regulate?
• How are devices approved?
• How does the TGA regulate devices once they are on the market?
Writing A Phase I Protocol: A Multidisciplinary Team ApproachSGS
A well-written and thought-out protocol is essential for achieving a high quality research study. To write this complete protocol, one must involve multiple key players from different disciplines, including: pharmacokinetics, toxicology, statisticians, modeling and simulation, and a biomarkers specialist. This approach will take additional time and resources, however the time spent on writing a detailed protocol will help to avoid problems and delays during the study conduct and will make publishing the results easier. A complete protocol is also essential for the study to be approved by the ethics committee. This presentation will explain the important roles of each team member in writing an early phase protocol.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
Patients Phase I Clinical Trials – Secured Multi Site Model for Key Populatio...SGS
Patient trials are receiving more focus in the early phase landscape. SGS strategy is to create robust and transparent capabilities to offer customized solutions for a wide range of patient trial requests. Enrollment potential, operational, excellence and completeness
in control are the key concerns for sponsors in this field. Beyond our CPU capabilities, we employ a network of Phase I Patient Units.
These units are located in hospitals both in Belgium and in the CEE region, where SGS own medical and support staff are present to ensure quality and professionalism in trial execution and SOPs are harmonized for full-scope transparency. Additional or alternative
solutions involve our regular cooperation and partnership with carefully selected recruitment expert CROs in order to access highly challenging patient pools or unique geographical locations.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
Pharma IQ brings you Clinical Trial Supply Europe Conference Profit. Successfully cutting costs and overages whilst increasing the flexibility and reactivity of your clinical supply network to support global clinical trials.
Complying with Wearable Health Device RegulationTGA Australia
Complying with Wearable Health Device Regulation
• Which devices does the TGA regulate?
• How are devices approved?
• How does the TGA regulate devices once they are on the market?
Writing A Phase I Protocol: A Multidisciplinary Team ApproachSGS
A well-written and thought-out protocol is essential for achieving a high quality research study. To write this complete protocol, one must involve multiple key players from different disciplines, including: pharmacokinetics, toxicology, statisticians, modeling and simulation, and a biomarkers specialist. This approach will take additional time and resources, however the time spent on writing a detailed protocol will help to avoid problems and delays during the study conduct and will make publishing the results easier. A complete protocol is also essential for the study to be approved by the ethics committee. This presentation will explain the important roles of each team member in writing an early phase protocol.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
Patients Phase I Clinical Trials – Secured Multi Site Model for Key Populatio...SGS
Patient trials are receiving more focus in the early phase landscape. SGS strategy is to create robust and transparent capabilities to offer customized solutions for a wide range of patient trial requests. Enrollment potential, operational, excellence and completeness
in control are the key concerns for sponsors in this field. Beyond our CPU capabilities, we employ a network of Phase I Patient Units.
These units are located in hospitals both in Belgium and in the CEE region, where SGS own medical and support staff are present to ensure quality and professionalism in trial execution and SOPs are harmonized for full-scope transparency. Additional or alternative
solutions involve our regular cooperation and partnership with carefully selected recruitment expert CROs in order to access highly challenging patient pools or unique geographical locations.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
Pharma IQ brings you Clinical Trial Supply Europe Conference Profit. Successfully cutting costs and overages whilst increasing the flexibility and reactivity of your clinical supply network to support global clinical trials.
The TGA Pharmacovigilance Inspection Pilot Program: 2015-2016TGA Australia
Firsthand overview of the TGA's Pharmacovigilance Inspection programme from the perspective of both the TGA and companies that have participated in the 'Pilot Inspection Programme'.
TGA Presentation: Medicines scheduling and scheduling policy ad hoc working g...TGA Australia
TGA Scheduling Working Group Meeting One February 2018. Role of the Working Group including Reforms to the advertising of S3 pharmacist only medicines, Reviewing what current S3 substances should be advertised, Proactively identifying S4 medicine substances for consideration for down-scheduling, Adding a new appendix to the poison standard to provide additional safeguards when down-scheduling
Impact of Sample Handling and Processing on Bioanalycial OutcomeSGS
Data from clinical assays (biomarkers, PK, PD, and immunogenicity) are often key outcomes from clinical trials. Implementing these endpoints in clinical trials is very costly and also time - and resource-consuming. Therefore, ensuring that appropriate measures are taken from the collection of samples until the completion of laboratory testing is paramount.
The purpose of this presentation is to discuss the challenges and potential pitfalls of sample collection, processing, and storage on the final bioanalytical endpoints and laboratory assays. Key parameters affecting various assay endpoints will be discussed and illustrated with specific examples, highlighting the SGS approach to handling and controlling these critical activities for the successful delivery of these studies outcomes.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
Regulatory Due Diligence, Using Regulatory Affairs to Maximize the Value of a...SGS
Developing a new drug is a costly undertaking, which can cost several hundreds of millions. Except for the largest Pharma companies, any other company will need external funding at some stage in the development of a drug. A solid regulatory strategy in early phase clinical research is essential to convince your investors to further fund the clinical development of your compound. Depending on your compound (chemical, biotech product, advanced therapy) and the type of investors (private investors, government funding bodies or a larger pharmaceutical company), different aspects of the regulatory strategy need to be more developed.
The main aspects of such an early phase regulatory strategy will be discussed and illustrated with a number of case studies such as the development of a regulatory strategy for a bacteriophage and discussions with Health Authorities.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
SME Assist: Help to navigate the regulatory mazeTGA Australia
Presentation to provide information on TGA’s SME Assist and what the service offers, details on upcoming SME Assist events and information on where to find more help
TGA Presentation: Data Metrics and Current Inspection TrendsTGA Australia
A discussion on the inspections close-out process, performance metrics and outcomes, inspection compliance outcomes, risk management, monitoring compliance, and common deficiencies found on inspections.
TGA presentation: Provisional approval pathway for prescription medicinesTGA Australia
This presentation provided an overview of some of the reform activities relevant to prescription, OTC and complementary medicines and implementation of recommendations from the Review of Medicines and Medical Devices Regulation including the content of the consultations on enhancements
Regulation of cell and tissue therapies and clinical research in AustraliaTGA Australia
This presentation provides an overview of biologicals including the process for inclusion on the Australian Register of Therapeutic Goods, and the regulation of clinical trials in Australia.
Join us in London next March for SMi Group's 9th annual MilSpace conference. Twenty Two speakers including a latest addition, Colonel Frank Scher, Chief Preparation for the Future, Joint Space Command will be taliking about French space capabilities outlook following the French White Paper 2013
The TGA Pharmacovigilance Inspection Pilot Program: 2015-2016TGA Australia
Firsthand overview of the TGA's Pharmacovigilance Inspection programme from the perspective of both the TGA and companies that have participated in the 'Pilot Inspection Programme'.
TGA Presentation: Medicines scheduling and scheduling policy ad hoc working g...TGA Australia
TGA Scheduling Working Group Meeting One February 2018. Role of the Working Group including Reforms to the advertising of S3 pharmacist only medicines, Reviewing what current S3 substances should be advertised, Proactively identifying S4 medicine substances for consideration for down-scheduling, Adding a new appendix to the poison standard to provide additional safeguards when down-scheduling
Impact of Sample Handling and Processing on Bioanalycial OutcomeSGS
Data from clinical assays (biomarkers, PK, PD, and immunogenicity) are often key outcomes from clinical trials. Implementing these endpoints in clinical trials is very costly and also time - and resource-consuming. Therefore, ensuring that appropriate measures are taken from the collection of samples until the completion of laboratory testing is paramount.
The purpose of this presentation is to discuss the challenges and potential pitfalls of sample collection, processing, and storage on the final bioanalytical endpoints and laboratory assays. Key parameters affecting various assay endpoints will be discussed and illustrated with specific examples, highlighting the SGS approach to handling and controlling these critical activities for the successful delivery of these studies outcomes.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
Regulatory Due Diligence, Using Regulatory Affairs to Maximize the Value of a...SGS
Developing a new drug is a costly undertaking, which can cost several hundreds of millions. Except for the largest Pharma companies, any other company will need external funding at some stage in the development of a drug. A solid regulatory strategy in early phase clinical research is essential to convince your investors to further fund the clinical development of your compound. Depending on your compound (chemical, biotech product, advanced therapy) and the type of investors (private investors, government funding bodies or a larger pharmaceutical company), different aspects of the regulatory strategy need to be more developed.
The main aspects of such an early phase regulatory strategy will be discussed and illustrated with a number of case studies such as the development of a regulatory strategy for a bacteriophage and discussions with Health Authorities.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
SME Assist: Help to navigate the regulatory mazeTGA Australia
Presentation to provide information on TGA’s SME Assist and what the service offers, details on upcoming SME Assist events and information on where to find more help
TGA Presentation: Data Metrics and Current Inspection TrendsTGA Australia
A discussion on the inspections close-out process, performance metrics and outcomes, inspection compliance outcomes, risk management, monitoring compliance, and common deficiencies found on inspections.
TGA presentation: Provisional approval pathway for prescription medicinesTGA Australia
This presentation provided an overview of some of the reform activities relevant to prescription, OTC and complementary medicines and implementation of recommendations from the Review of Medicines and Medical Devices Regulation including the content of the consultations on enhancements
Regulation of cell and tissue therapies and clinical research in AustraliaTGA Australia
This presentation provides an overview of biologicals including the process for inclusion on the Australian Register of Therapeutic Goods, and the regulation of clinical trials in Australia.
Join us in London next March for SMi Group's 9th annual MilSpace conference. Twenty Two speakers including a latest addition, Colonel Frank Scher, Chief Preparation for the Future, Joint Space Command will be taliking about French space capabilities outlook following the French White Paper 2013
SMi Group announces the return of its 11th annual Pharmaceutical Logistics conference to London on the 18th- 19th May 2017. Outsourcing logistics tasks to third parties has been observed as an emerging trend in the global market and it is only expected to gain momentum in the coming years
The 11th edition of Patient Safety Middle East Conferences and Exhibition will be held in Dubai 04-06 October 2015 to facilitate the improvement of patient safety and reduction of medical errors in the Middle East.
ExL Pharma Clinical Trials Phase I and Phase IIa Conference Brochure: Phase 1...bryonmain
There is a pill or treatment for almost everything, or at least, that is how it seems. However, the amount of effort that goes into a pill or treatment before it is launched is extensive, expensive and often inefficient.
Efficiency and innovation go hand-in-hand with R&D and the development of clinical trials, however, FDA regulations and clinical trial standardization end up stifling these two key factors. This leads to drawn out processes that cost companies hundreds of millions of dollars before the drugs hit the market. Efforts have been made to increase efficiency in phase I/IIA with some companies changing their clinical trial manifestos to suit the available patient population at clinical sites, but more emphasis should be placed on creating more efficient processes for first in human studies by optimizing pharmacokinetics/pharmacodynamics, dosage selection, technological advancements to improve efficacy and structured patient mapping to increase successful trial and patient recruitment opportunities.
This program will give delegates the opportunity to share proven strategies between companies to help increase efficiency in this space and streamline processes to cut down costs. This event will bring together large and small companies and experts in this space to share best practices to decrease the financial drain theses phases have on the overall clinical trial budget. Life science corporations need the most up-to-date tools and practices to increase success by streamlining processes, sharing successful biomarker strategies, anticipating dosing quantities, and optimizing healthy or specialty patient recruitment and retention. Current strategies include patient mapping before organizing and setting up a clinical space, tailoring early phase clinical trials to patient populations, purchasing biological samples from collection companies, and trying to accelerate the process by submitting for breakthrough therapy designation.
Top Reasons To Attend
Identify Compound Development Strategies to Optimize Success in Clinical Trials
Learn Best Practices for Early Decision-Making Through Analysis of Biomarker Utility in Drug Development
Utilize Analytical Technology to Evaluate Multiple Configurations of a Small Molecule to Increase the Feasibility of Drug in Clinical Trials
Implement Adaptive Design in Proof of Concept Studies to Increase Efficiency, Decrease Time and Decrease Overall Cost
Explore the Seamless Development of Phase I to Phase II in Clinical Trials
NINE Case Studies and a Panel Session on Early Phase Clinical Trial Strategies
This is a presentation by Dada Robert in a Your Skill Boost masterclass organised by the Excellence Foundation for South Sudan (EFSS) on Saturday, the 25th and Sunday, the 26th of May 2024.
He discussed the concept of quality improvement, emphasizing its applicability to various aspects of life, including personal, project, and program improvements. He defined quality as doing the right thing at the right time in the right way to achieve the best possible results and discussed the concept of the "gap" between what we know and what we do, and how this gap represents the areas we need to improve. He explained the scientific approach to quality improvement, which involves systematic performance analysis, testing and learning, and implementing change ideas. He also highlighted the importance of client focus and a team approach to quality improvement.
How to Create Map Views in the Odoo 17 ERPCeline George
The map views are useful for providing a geographical representation of data. They allow users to visualize and analyze the data in a more intuitive manner.
How to Split Bills in the Odoo 17 POS ModuleCeline George
Bills have a main role in point of sale procedure. It will help to track sales, handling payments and giving receipts to customers. Bill splitting also has an important role in POS. For example, If some friends come together for dinner and if they want to divide the bill then it is possible by POS bill splitting. This slide will show how to split bills in odoo 17 POS.
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
Ethnobotany and Ethnopharmacology:
Ethnobotany in herbal drug evaluation,
Impact of Ethnobotany in traditional medicine,
New development in herbals,
Bio-prospecting tools for drug discovery,
Role of Ethnopharmacology in drug evaluation,
Reverse Pharmacology.
The Roman Empire A Historical Colossus.pdfkaushalkr1407
The Roman Empire, a vast and enduring power, stands as one of history's most remarkable civilizations, leaving an indelible imprint on the world. It emerged from the Roman Republic, transitioning into an imperial powerhouse under the leadership of Augustus Caesar in 27 BCE. This transformation marked the beginning of an era defined by unprecedented territorial expansion, architectural marvels, and profound cultural influence.
The empire's roots lie in the city of Rome, founded, according to legend, by Romulus in 753 BCE. Over centuries, Rome evolved from a small settlement to a formidable republic, characterized by a complex political system with elected officials and checks on power. However, internal strife, class conflicts, and military ambitions paved the way for the end of the Republic. Julius Caesar’s dictatorship and subsequent assassination in 44 BCE created a power vacuum, leading to a civil war. Octavian, later Augustus, emerged victorious, heralding the Roman Empire’s birth.
Under Augustus, the empire experienced the Pax Romana, a 200-year period of relative peace and stability. Augustus reformed the military, established efficient administrative systems, and initiated grand construction projects. The empire's borders expanded, encompassing territories from Britain to Egypt and from Spain to the Euphrates. Roman legions, renowned for their discipline and engineering prowess, secured and maintained these vast territories, building roads, fortifications, and cities that facilitated control and integration.
The Roman Empire’s society was hierarchical, with a rigid class system. At the top were the patricians, wealthy elites who held significant political power. Below them were the plebeians, free citizens with limited political influence, and the vast numbers of slaves who formed the backbone of the economy. The family unit was central, governed by the paterfamilias, the male head who held absolute authority.
Culturally, the Romans were eclectic, absorbing and adapting elements from the civilizations they encountered, particularly the Greeks. Roman art, literature, and philosophy reflected this synthesis, creating a rich cultural tapestry. Latin, the Roman language, became the lingua franca of the Western world, influencing numerous modern languages.
Roman architecture and engineering achievements were monumental. They perfected the arch, vault, and dome, constructing enduring structures like the Colosseum, Pantheon, and aqueducts. These engineering marvels not only showcased Roman ingenuity but also served practical purposes, from public entertainment to water supply.
Model Attribute Check Company Auto PropertyCeline George
In Odoo, the multi-company feature allows you to manage multiple companies within a single Odoo database instance. Each company can have its own configurations while still sharing common resources such as products, customers, and suppliers.
The Indian economy is classified into different sectors to simplify the analysis and understanding of economic activities. For Class 10, it's essential to grasp the sectors of the Indian economy, understand their characteristics, and recognize their importance. This guide will provide detailed notes on the Sectors of the Indian Economy Class 10, using specific long-tail keywords to enhance comprehension.
For more information, visit-www.vavaclasses.com
1. BOOK BY Y TO
RUAR
28TH FEB
0
0
SAVE £3
BOOK BY TO
CH
1ST MAR
3
0
0
SAVE £1
SMi presents the 8th conference
and exhibition series...
Clinical Trial Logistics
21ST - 22ND MAY 2014 | MARRIOTT REGENTS PARK | LONDON, UK
EUROPE'S LEADING CLINICAL TRIAL LOGISTICS EVENT
KEY SPEAKERS:
• Lesley George, Supply Chain Lead, Pfizer
• Riekert Bruinink, Member of the GDP drafting Group of the
EMA, Dutch Health Care
• Vimal Unewal, Planning manager, Ferring Pharmaceuticals Ltd
• Vanessa Simm, Senior Operations Manager, Allergan
• Frauke Bruns, Clinical Trial Supplies Group Leader, Actelion
Pharmaceuticals
• Janice Kite, Traceability Director Healthcare, GS1
• Layla Hannbeck, Head of Pharmacy Services, National
Pharmaceutical Association
• Andrea Gruber, Manager Business Process & Standards, IATA
And many more…
NEW EXPANDED EVENT FOR 2014:
• More panel discussions, more case studies and more speakers
than ever before
• Find out the latest information on GDP regulations and their
application to clinical trials
• In its 8th year this is the longest established Clinical Trial Logistics
event globally
• Enhanced networking for delegates through the use of roundtables
• Focus sessions on GDP regulations and trials in emerging markets
• Refreshed programme focusing on the latest issues
from across the globe
PHARMA
ATTEND FOR:
£999
PLUS INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOP
A: Virtual logics: Managing quality and user acceptance testing
Tuesday 20th May 2014, Marriott Regents Park, London, UK
Workshop Leader: Nimer Yusef, Consultant and Founder, Trial-Brain
12.30pm - 4.30pm
Sponsored by
www.clinical-trial-logistics.com
Register online or fax your registration to
+44 (0) 870 9090 712 or call +44 (0) 870 9090 711
2. Clinical Trial Logistics 2014
DAY ONE | 21ST MAY 2014
8.30
REGISTRATION & COFFEE
9.00
12.10
Chairman's Opening Remarks
Networking Lunch in the exhibition area
SUPPLY CHAIN EFFICIENCY AND OPPORTUNITIES
Andrea Gruber, Manager Business Process & Standards,
IATA
1.50
Managing supply chain efficiency
• When should you have your regulatory process in place
OPENING ADDRESS / KEYNOTE ADDRESS
9.30
• Which nations should you plan individually
Dispelling the myths on GDP compliance in clinical trials
• What risks can you plan for
• Legal requirements or best practices: A look at
Vimal Unewal, Planning Manager, Ferring
variation between EU member states
Pharmaceuticals Ltd
• What is legally required
• What is likely to be enforced
Riekert Bruinink, Member of the GDP drafting Group of
2.30
How can you optimise pharmaceutical road transit
• Current supply chain challenges
the EMA, Dutch Health Care Inspectorate
• Where are the delays occurring?
10.10
• What can you do to reduce cost and optimise
Morning refreshments and networking in the
deliveries
exhibition area
Peter J Cullum, Head of International Affairs, Road
10.40
Haulage Association
PANEL: Clinical trial supply chain challenges and
comparisons
• What measures do you have to consider with a clinical
3.10
Afternoon refreshments in the exhibition area
3.40
NPA: How can big pharma support pharmacy distribution
trial chain compared to a commercial chain?
• How and when should your CTL comply with GDP
regulations?
in product development stages?
• Managing temperature controlled products in
• About the NPA
emerging markets
• Key challenges in pharmacy supply
Moderator: Bob Hayes, Director, Cold Chain Consultants
• EU distribution challenges
PANEL
Panellists:
Layla Hannbeck, Head of Pharmacy Services, National
Vanessa Simm, Senior Operations Manager, Allergan
Pharmaceutical Association
Vimal Unewal, Planning manager, Ferring
Pharmaceuticals Ltd
4.20
KEYNOTE SESSION: Overcoming key inefficiencies in your
Director, University of Glasgow
11.30
GS1 Standards: Enabling supply efficiency
• Who we are and what we do
• The case for global supply chain standards
• Enabling regulatory compliance, e.g. EU Falsified
Medicines Directive
AFTERNOON KEYNOTE
Prof. Dr. Vladimir V. Anisimov, Sr Strategic Biostatistics
supply chain
• How can efficient management ensure cost savings in
CTS chains?
• Effectively monitor delays in trial shipping
• Identifying your weak spots and how to overcome
these
Harvey Rubin, Professor of Medicine, Microbiology and
Computer Science, University of Pennsylvania
• Improving Patient Safety and Supply Chain Security
through Traceability: Products, People, Processes
Janice Kite, Traceability Director Healthcare, GS1
5.00
Chairman's Closing Remarks and Close of Day One
Register online at: www.clinical-trial-logistics.com •
Platinum Media Partner
Gold Media Partner
Silver Media Partner
Supporting Associations
Supported by
3. DAY TWO | 22ND MAY 2014
8.30
REGISTRATION & COFFEE
9.00
Clinical Trial Logistics 2014
1.50
Chairman's Opening Remarks
Managing your cold chain in clinical trials
• Managing air transportation challenges
• Utilising validated transportation solutions
Andrea Gruber, Manager Business Process & Standards, IATA
• Importance of cold chain in avoiding wastage and
OPENING ADDRESS / KEYNOTE ADDRESS
9.10
legitimising trials
Managing the challenges of clinical supplies in third
Bev Nicol, Distribution Specialist, Pfizer
party blinded studies
• Review of different scenarios that may be encountered
• What are the options when defining your blinding
strategy?
2.30
PANEL: Discussing efficient methods used when labelling
and packaging products
Lesly George, Supply Chain Lead, Pfizer
• What’s the right solution for global labelling
MANAGING RISK IN THE SUPPLY CHAIN
9.50
PANEL
• What can go wrong? Identifying risks and mitigations
Logistical challenges and strategies for emerging
inefficiency?
• Managing time and temperature sensitive labelling
Peter J Cullum, Head of International Affairs, Road
markets: Russia and Ukraine
Haulage Association
• Case studies in emerging markets for clinical trials
• How to accelerate clinical trials
• Supply chain optimization
3.10
Afternoon refreshments in the exhibition area
3.40
INTERACTIVE ROUND TABLE: Crisis management:
Angus McLeod, Sr. Manager, CTS, Catalent
10.30
Morning coffee and refreshments in the exhibition area
11.00
CASE STUDY: Overcoming challenges in the clinical
What to do when the worst has come to pass
supply chain
• Best practices when dealing with crises
• Identifying a smart approach to ambient temperature
• How can you ensure trial validity
controlled shipments
• What you can do to get back on track
• At which development stage does a switch from cost
Bob Hayes, Director, Cold Chain Consultants
CASE STUDY
of goods to transfer prices make commercial sense
• How can we implement the IVRS in a smart way, with
regards to costs, for reconciliation
4.20
Avoiding counterfeit medicines entering trials
Frauke Bruns, Clinical Trial Supplies Group Leader,
• Falsified Medicines Directive and its impact on logistics
Actelion Pharmaceuticals
•Opportunities and threats
CASE STUDY
11.40
12.20
CASE STUDY: Clinical Trial Supply Chain & Risk
• How to protect your supply chain
• Not Measuring the Risk
• Tools to measure Risk
Mike Isles, Executive Director, European Alliance for
• Which Risk Level is acceptable
Access to Safe Medicines
Nimer Yusef, Consultant and Founder, Trial-Brain
Networking Lunch in the exhibition area
5.10
Chairman’s Closing Remarks and Close of Day Two
Fax: +44 (0)870 9090 712 • Tel: +44 (0)870 9090 711
4. HALF-DAY PRE-CONFERENCE PM WORKSHOP
TUESDAY 20TH MAY 2014 | MARRIOTT REGENTS PARK | LONDON, UK
A: Virtual logics: Managing quality and
user acceptance testing
Workshop Leader: Nimer Yusef, Consultant and Founder, Trial-Brain
Overview
Learn how to effectively approach UATs for IVRS in clinical Trials. Why are we performing UAT, how we are performing them
and what tools you need to support them. And get a glimpse in to what happens and can happen during UAT and how
to deal with it.
Agenda
12.30
Registration & Coffee
1.00
Welcome & Introductions
1.10
Session 1
Why performing IVRS UATs
• Regulatory Background
• Why IVRS is so critical
1.45
2.45
Session 3
Support your UAT
• Processes Overview
• Tools you need
3.40
Session 4
The UAT
• Examples
• Typicals Problems and how to deal with them
4.20
Chairman’s Closing Remarks
4.30
Session 2
The Performance
• Case Studies
• Vendor Scripts
3.00
Close of Workshop
Refreshment break
About the workshop host
My name is Nimer Yusef, I am a mathematician with a strong IT background. I had my first contact with the clinical
research industry in 1998 at the CRO ICRC Weyer. From 2002 to 2012 I worked for Parexel International in the areas of IVRS
and Clinical Trial Logistics, holding different positions. I was involved as software developer and validation engineer for
IVRS. I experienced all the day to day problems with these systems and was also responsible for the 24/7 hotline, which
enabled me to identify and solve the key issues for the business. Later I took over responsibility as project manager for the
setup and operations of these systems and developed innovative systems in the area of Inventory Management,
Dynamic Labeling, Cold Chain Management and the regular requirements for narcotics in Germany. I gained essential
experiences as a Clinical Trial Supply Manager and was responsible for the setup of studies in the area of Clinical Trial
Supply, which has influenced my perspective of IVRS in clinical trials dramatically. Within the logistics department, I was
responsible for the training and coaching of colleagues for the implementation of clinical studies with IVRS. This included
the study setup, change implementation and trouble shooting. I trained and mentored colleagues to take over
responsibility as IVRS consultants. Moreover, I developed standards with IVRS vendors. Since 2010 I offer my expertise as
an independent trainer & consultant under the label Trial Brain. I operate on the tactical as well as on the strategical level.
I am also an expert in the area of Clinical Supply Simulations and Forecasting.
About Trial Brain
Trial Brain is a management organization that can perform up to the full IVRS Management from
Vendor Selection through URS development to study conduct including also UAT preparation and
performance. It is support from highly professional trainings in the area of IVRS & Logistics in
Clinical Trials.
5. Clinical Trial Logistics 2014
Enhanced
Networking
Renewed
Programme
More networking
lunches, dinners and
roundtable discussions to
help you build new
contacts and strengthen
existing relationships
Focus your business plans
with discussions from some
of the leading figures in
Clinical Trial Logistics and
supply globally
existing relationships
Interactive Panel
Discussions
Share your view points,
and have your questions
answered during
interactive debate
sessions
Online networking
Maximise your
effectiveness at the
conference by contacting
delegates before the
event on the dedicated
LinkedIn Group
Clinical Trial
Logistics:
Enhanced
Workshop
Gain in-depth
knowledge and advice
in how to solve the key
challenges affecting your
supply chain by
attending our half day
workshop
World leading
exhibition
Featuring the leading
logistics partners and
suppliers to the
pharmaceutical industry
globally
Sponsored by
Berlinger & Co AG is a leading Swiss manufacturer of temperature monitoring systems. For more
than 25 years, Berlinger & Co. AG provides the industry with reliable and easy to use temperature
indicators. With our online data management & central monitoring solution „smartview“, you can
optimize your workflow and automate process steps. All our systems are WHO/UNICEF approved.
www.berlinger.ch
Catalyst Tailored solutions from a global leader. With more than 25 years of clinical trial supply
experience, we have the resources and expertise to deliver cost effective and time sensitive
solutions around the world. Whether you are seeking standalone support or a comprehensive
package, we have the right solution for you. www.catalent.com
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company's
marketing strategy. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences
please call: Alia Malick, SMi Sponsorship on +44 (0)20 7827 6168 or email: amalick@smi-online.co.uk
6. CLINICAL TRIAL LOGISTICS 2014
Conference: Wednesday 21st and Thursday 22nd May 2014, Marriott Regents Park Hotel, London, UK
Workshop: Tuesday 20th May 2014, London
4 WAYS TO REGISTER
www.clinical-trial-logistics.com
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
EARLY BIRD □
DISCOUNT □
Book by 28th February to receive a £300 discount off the conference price
Book by 31st March to receive a £100 discount off the conference price
CONFERENCE PRICES
Unique Reference Number
Our Reference
I would like to attend: (Please tick as appropriate)
Commercial Organisations
□ Conference & Workshop
□ Conference only
□ Workshop only
LV P-106
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title:
Forename:
Surname:
Job Title:
Fee
Total
£2098.00 +VAT
£1499.00 +VAT
£599.00 +VAT
£2517.60
£1798.80
£718.80
Pharmaceutical Companies
□ Conference & Workshop
□ Conference only
□ Workshop only
£1598.00 +VAT
£999.00 +VAT
£599.00 +VAT
£1917.60
£1198.80
£718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees
£999.00
Department/Division:
Company/Organisation:
+ VAT
£1198.80
Email:
The conference fee includes refreshments, lunch, conference papers and access
to the Document Portal containing all of the presentations.
Company VAT Number:
Address:
LIVE STREAMING/ON DEMAND/ DOCUMENTATION
Town/City:
Post/Zip Code:
Unable to travel, but would like to watch the conference live, ask questions,
participate as if you were in the room.
Price
Total
Country:
Direct Tel:
Direct Fax:
□ Live Streaming
□ On demand
Mobile:
Switchboard:
£999.00 + VAT (UK) £1198.80
£599.00 + VAT (UK) £718.80
(available 24 hours after the event)
Signature:
Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
on the Document Portal
£499.00 + VAT
£499.00 (or only £300 if ordered with the Document Portal)
□ The Conference Presentations - paper copy
ACCOUNTS DEPT
Title:
□ Access to the conference documentation
Forename:
£598.80
£499.00
Surname:
PAYMENT
Email:
Address (if different from above):
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-106 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
Town/City:
Post/Zip Code:
Country:
Direct Tel:
Direct Fax:
VENUE
Marriott Hotel Regents Park, 128 King Henry's Road, London, NW3
3ST
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
Terms and Conditions of Booking
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be
paid immediately and prior to the start of the event. If payment has not been received then credit
card details will be requested and payment taken before entry to the event. Bookings within 7 days
of event require payment on booking. Access to the Document Portal will not be given until payment
has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we have
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
products and services. Unless you tick here □ we may also share your data with third parties offering
complementary products or services. If you have any queries or want to update any of the data that
we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit
our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the
attached letter.
□ UK BACS
□ Wire Transfer
□ Cheque
□ Credit Card
Sort Code 300009, Account 00936418
Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
We can only accept Sterling cheques drawn on a UK bank.
□ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
□□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Card No:
Cardholder’s Name:
Signature:
Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live
Streaming, on Demand, Document portal and literature distribution for all UK customers and
for those EU Customers not supplying a registration number for their own country here.
______________________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk